Rep. Thomas H. Kean, Jr. Sells Off Shares of Stryker Corporation (NYSE:SYK)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on September 30th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Stryker Trading Up 1.7%

Shares of SYK stock traded up $5.15 during mid-day trading on Tuesday, reaching $311.96. 591,713 shares of the stock traded hands, compared to its average volume of 2,469,291. The stock’s fifty day simple moving average is $292.37 and its two-hundred day simple moving average is $324.26. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a market cap of $119.66 billion, a price-to-earnings ratio of 33.25, a price-to-earnings-growth ratio of 1.96 and a beta of 0.78. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.19 earnings per share. On average, research analysts anticipate that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: JPMorgan lowered its price target to $340 from $350 but maintained an Overweight rating, implying approximately 10.8% upside from the referenced price. This indicates the firm still views Stryker’s long-term growth prospects favorably.
• Positive Sentiment: Barclays reaffirmed its Buy rating, providing some support despite broader target-price reductions among analysts. Barclays Reaffirms Their Buy Rating on Stryker
• Neutral Sentiment: TipRanks continues to provide updated analyst forecasts and price-target coverage for Stryker, reflecting ongoing reassessment following the company’s recent results. Stryker Stock Forecast and Price Target
• Negative Sentiment: Truist reaffirmed a Hold rating and reduced its price target to $305 from $310, suggesting limited near-term upside. Truist Reaffirms Hold Rating on Stryker
• Negative Sentiment: Several firms also trimmed their targets: Citizens JMP, Citigroup, TD Cowen and Barclays. Canaccord Genuity additionally downgraded Stryker to Hold. The broad pattern suggests analysts are lowering expectations after Q3 guidance and the recent earnings miss. Citizens JMP Cuts Stryker Price Target Citigroup Trims Stryker Price Target TD Cowen Cuts Stryker Price Target Barclays Cuts Stryker Price Target Canaccord Cuts Stryker to Hold
• Negative Sentiment: A report noted that Stryker’s estimated fair value declined as analysts reset expectations following Q3 guidance, reinforcing valuation pressure on the shares. Stryker Fair Value Falls After Analysts Reset Expectations

Institutional Trading of Stryker

Several hedge funds have recently bought and sold shares of SYK. Gables Capital Management Inc. purchased a new stake in shares of Stryker in the second quarter worth approximately $25,000. Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter valued at approximately $25,000. Highland Investment Advisors LLC purchased a new stake in Stryker in the second quarter worth $25,000. Cornerstone Financial Management LLC raised its stake in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares during the period. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at approximately $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SYK. UBS Group began coverage on shares of Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Raymond James Financial reissued an “outperform” rating and set a $323.00 target price on shares of Stryker in a research report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a report on Thursday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research report on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $355.04.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronda Stryker sold 300,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last quarter. 4.60% of the stock is currently owned by corporate insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.